Quarterly ResultMay 7, 2026, 07:33 AM
Lexicon Q1 Net Loss $1.0M; $199.7M Cash; Key Pipeline Milestones Ahead
AI Summary
Lexicon Pharmaceuticals reported a significantly reduced net loss of $1.0 million for Q1 2026, compared to $25.3 million in Q1 2025, driven by $20.0 million in licensing and milestone revenue. Total revenues reached $21.1 million. The company ended the quarter with a strong cash position of $199.7 million, bolstered by a $96.5 million stock sale and a new $100 million loan facility. Lexicon anticipates key clinical milestones, including SONATA-HCM enrollment completion mid-2026, ZYNQUISTA NDA resubmission mid-2026, and continued development of LX9851 by Novo Nordisk.
Key Highlights
- Q1 2026 net loss significantly reduced to $1.0 million from $25.3 million year-over-year.
- Total revenues for Q1 2026 increased to $21.1 million, including $20.0 million in milestone revenue.
- Cash, investments, and restricted cash totaled $199.7 million as of March 31, 2026.
- Secured a new $100 million loan facility with Hercules Capital, with an initial $55 million tranche funded.
- SONATA-HCM Phase 3 enrollment expected to complete mid-2026; topline results in Q1 2027.
- ZYNQUISTA NDA resubmission for type 1 diabetes anticipated mid-2026 for potential approval.
- Novo Nordisk initiated Phase 1 study for LX9851, triggering a $10 million milestone payment.
- R&D expenses decreased to $12.8 million and SG&A expenses to $9.2 million in Q1 2026.